Special Issue "Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0"

Valentina Gandin; James D Hoeschele; Nicola Margiotta

doi:10.3390/ijms24097917

Special Issue "Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0"

Int J Mol Sci. 2023 Apr 27;24(9):7917. doi: 10.3390/ijms24097917.

Authors

Valentina Gandin¹, James D Hoeschele², Nicola Margiotta³

Affiliations

¹ Department of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, 35131 Padua, Italy.
² Department of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, USA.
³ Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, 70125 Bari, Italy.

Abstract

The year 2023 marks the 45th year since FDA approval of cisplatin as an anticancer drug, and, at present, it is widely used against a spectrum of human tumors, including early-stage ovarian cancer, non-small cell lung cancer (typically developed by smokers), head and neck, and advanced bladder cancer [...].

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Carcinoma, Non-Small-Cell Lung*
Cisplatin / pharmacology
Cisplatin / therapeutic use
Head and Neck Neoplasms*
Humans
Lung Neoplasms* / drug therapy
Urinary Bladder Neoplasms*

Substances

Cisplatin
Antineoplastic Agents